Commercial Considerations For Cell And Gene Therapies: Viewpoints From The 2016 ARM Meeting
There are still many lessons to be learned in commercializing cell and gene therapies. Experts in the industry discussed challenges and best practices at the Alliance for Regenerative Medicine's annual meeting in October.
You may also be interested in...
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.